Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDH17-targeted radioligand therapy
- Development stage
- Preclinical
- Lead developer
- Corellia AI
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDH17-targeted radioligand therapy is an experimental radiopharmaceutical being developed for the treatment of gastrointestinal malignancies, including colorectal, gastric, and pancreatic cancers. It utilizes a fully human monoclonal antibody scaffold to target Cadherin 17 (CDH17), a cell surface protein highly expressed in these tumors. By delivering a radioactive payload directly to CDH17-expressing cells, the therapy aims to overcome resistance observed with microtubule and topoisomerase I inhibitor-based antibody-drug conjugates (ADCs). Preclinical data presented by Corellia AI and Champions Oncology demonstrate potent efficacy in patient-derived xenograft (PDX) models, including those refractory to Deruxtecan-based ADCs.
- Other names
- CDH17-targeted RLTCDH-17-targeted RLTCDH 17-targeted RLT
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on CDH17-targeted radioligand therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH17-targeted radioligand therapy.